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doi: 10.1016/j.exphObjective. Megakaryopoiesis and platelet formation is a multistep process through which
hematopoietic progenitor cells develop into mature megakaryocytes (MKs) and form propla-
telets. The present study investigates the regulation of different steps of megakaryopoiesis (i.e.,
differentiation, migration, and proplatelet formation) by extracellar signal-regulated kinase
(ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) in two models of primary
murine MKs derived from bone marrow (BM) cells and fetal liver (FL) cells.
Materials and Methods. A preparation of MKs was generated from BM obtained from femora
and tibiae of C57BL6 mice. FL-derived MKs were obtained from the liver of mouse fetuses
aged 13 to 15 days.
Results. For both cell populations, activation of MEK-ERK1/2 pathway by thrombopoietin
was found to have a critical role in MK differentiation, regulating polyploidy and surface
expression of CD34, GPIIb, and GPIb. The MEK-ERK1/2 pathway plays a major role in
migration of BM-derived MKs toward a stromal-cellLderived factor 1a (SDF1a) gradient,
whereas unexpectedly, FL-derived cells fail to migrate in response to the chemokine due to
negligible expression of its receptor, CXCR4. The MEK-ERK1/2 pathway also plays a critical
role in the generation of proplatelets. In contrast, p38MAPK pathway was not involved in any
of these processes.
Conclusion. This report demonstrates a critical role of MEK-ERK1/2 pathway in MK differ-
entiation, motility, and proplatelet formation. This study highlights several differences
between BM- and FL-derived MKs, which are discussed.  2009 ISEH - Society for Hema-
tology and Stem Cells. Published by Elsevier Inc.Megakaryopoiesis is a tightly controlled multistep process
of proliferation and differentiation involving commitment
of hematopoietic multipotent progenitor cells to megakar-
yocyte (MK) precursors followed by maturation and (pro)-
platelet formation. During development, MKs undergo
a series of transformations that can be identified by expres-
sion of surface proteins, including GPIIb (also known as the
integrin subunit aIIb or CD41) and GPIb (CD42b), in asso-d Se´verin contributed equally to this work.
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em.2009.07.006ciation with nuclear maturation characterized by successive
rounds of endomitosis and subsequent cytoplasmic matura-
tion. The end result is large polyploid MKs, characterized
by long, branching cytoplasmic extensions called proplate-
lets, which give rise to platelets [13].
Thrombopoietin (TPO) is a crucial regulator of megakar-
yocytic growth and differentiation in vitro and in vivo, ex-
erting its effects through its receptor, c-Mpl [47]. c-Mpl
signals via the Janus kinase/signal transducer and activator
of transcription (JAK/STAT) [8] and Shc-Rasmitogen-
activated protein kinase (MAPK) pathways [9,10]. Several
studies have reported a critical role for JAK2 and STAT5
in mediating MK development downstream of c-Mpl.
Further, the V617F mutant of JAK2 is the causative muta-
tion in approximately 50% of patients with the myeloprolif-
erative disorder, essential thrombocythemia (ET), which is
characterized by an increase in platelet count [1113].ology and Stem Cells. Published by Elsevier Inc.
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extracellular signal-regulated kinases (ERKs), p38MAPKs
and c-Jun amino-terminal kinases (JNKs) families [14],
which are activated by dual phosphorylation of threonine
and tyrosine residues. These three MAPK pathways are
implicated in proliferation, survival, differentiation, and
apoptosis of a wide variety of cells. The importance of
the ERK1/2 pathway in MK differentiation was analyzed
by expression of constitutively active or dominant-negative
mutants of the upstream regulator of ERK1/2 kinases,
MEK, and by use of pharmacological inhibitors of MEK
(e.g., PD98059 and U0126) in immortalized megakaryo-
cytic cell lines, including UT7-TPO [15], K562 [1618],
CMK [19], and in primary human MKs derived from
cord or peripheral blood hematopoietic progenitor cells
[2023] and primary mouse bone marrow (BM)derived
MKs [24]. A general consensus is that the MEK-ERK1/2
pathway acts as a regulator of differentiation in MKs, prin-
cipally promoting polyploidization in the later develop-
mental stage [1519,21,23,24]. Conflicting results on the
role of MEK-ERK1/2 pathway on the differentiation of
primary MKs have been published [20,22]. In addition,
inhibition of ERK1/2 has been shown to increase [25],
inhibit [26], or have no effect [27] on proplatelet formation
in different MK models. These discrepancies may be due to
the experimental conditions, the source of cells, or the
concentration of the MEK inhibitors. In comparison, the
role of the p38MAPK pathway in MK growth and differen-
tiation has not been as extensively investigated and its
various roles, if any, remain unclear [23,28,29].
This present study was undertaken to directly compare
two primary mouse MK models derived from BM- and fetal
liver (FL)-progenitor cells using established culture
methods. The role of ERK1/2 and p38MAPK pathways in
MK differentiation, migration, and proplatelet formation
has been analyzed.Materials and methods
Reagents, antibodies, and suppliers (detailed
information can be found in Supplementary Methods)
MK purification and culture
Mature MKs from BM- and FL- cells were defined as the popula-
tion of cells generated using the methodology of the Frampton and
Shivdasani laboratories, respectively [30,31]. In brief, BM cells
were obtained from femora and tibiae of C57BL6 mice by flush-
ing, and cells expressing one or more of the following surface
proteins, CD16/CD32þ, Gr1þ, B220þ, CD11bþ, were depleted
using immunomagnetic beads (sheep anti-rat IgG Dynabeads; In-
vitrogen, Paisley, UK). The remaining population was cultured in
2.6% serum-supplemented Stempro medium with 2 mM L-gluta-
mine, penicillin/streptomycin, and 20 ng/mL murine stem cell
factor (SCF) at 37C under 5% CO2 for 2 days. Cells were then
cultured for an additional 4 days in the presence of 20 ng/mL
murine SCF and 100 ng/mL murine TPO [30,32]. FL cells wereobtained from whole livers recovered from mouse fetuses between
embryonic days 13 and 15. Single-cell suspensions were prepared
by successive passage through 19-, 22-, and 25-gauge needles and
cultured in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, penicillin/strep-
tomycin, and 100 ng/mL murine TPO for 5 days [31]. After 4 to 5
days of culture in the presence of TPO, the cell population was en-
riched in mature MKs using a 1.5%/3% bovine serum albumin
(BSA) gradient under gravity (1g) for 45 minutes at room temper-
ature. The proportion of mature MKs in the enriched population
was estimated to be O60% (data not shown). To study the role
of MAPKs in differentiation, inhibitors were added at the same
time as TPO, and this was taken as the beginning of the differen-
tiation process. The inhibitor was then given again after 24 hours
at the same concentration (see Supplementary Fig. E1 [online
only, available at www.exphem.org] for time course of differenti-
ation and addition of reagents). An equivalent amount of dimethyl
sulfoxide (!0.1%) or indomethacin (5 mM) were added to the
control cells as stated in the text and figure legends.
MK biochemistry
After differentiation and BSA gradient isolation, mature MKs
were harvested 4 hours at 37C in serum-free media. Whole-cell
lysates were prepared from MKs stimulated by TPO (50 ng/mL)
or from BSA nonadherent and fibrinogen adherent MKs for the
indicated times. Proteins were resolved on 4% to 12% NuPAGE
Bis-Tris gradient gels and immunoblotted with primary antibodies
and horseradish peroxidaseconjugated secondary antibody.
Proteins were detected by enhanced chemiluminescence and
autoradiography.
Flow cytometry
Expression levels of CD34, GPIIb, GPIb, and CXCR4 were
measured by flow cytometry using specific antibodies. Polyploidy
of mature MKs isolated by BSA gradient was analyzed after anti-
GPIIb labeling and DNA staining with propidium iodide. GPIIb-
positive cells were gated to analyze DNA content. Samples were
acquired using FACSCalibur flow cytometer and CellQuest
software (Becton Dickinson, Oxford, UK) and analyzed using
Summit v4.3 software (DAKO, Cambridge, UK).
Cell migration assay
Chemotaxis was assessed using the Dunn chamber (Weber Scien-
tific International, Teddington, UK) as described previously [32]
and detailed in Supplementary Methods. To investigate the role
of ERK1/2 and p38MAPK in migration, the Dunn chamber outer
well was refilled with the medium containing stromal-
cellderived factor 1a (SDF1 a; 300 ng/mL) and the specific
inhibitors, PD184161 (10 mM) or SB203580 (10 mM). Time-lapse
images were digitally captured every minute for 4 hours using
a Zeiss 20 1.40 NA plan-apochromat lens on a Zeiss Axiovert
200 inverted high-end microscope (Welwyn Garden City, UK)
and a Hamamatsu Orca 285 cooled digital camera. Slidebook
and Image J softwares were used to acquire and process images.
Proplatelet formation assay
Fibrinogen-coated coverslips were prepared as described previously
[33] by incubating overnight with fibrinogen (100 mg/mL) at 4C and
blocking with denatured BSA (5 mg/mL) in phosphate-buffered
saline. Mature MKs were incubated for 15 minutes with MEK-
Figure 1. Time course of thrombopoietin (TPO)-induced extracellular regulated kinase (ERK)1/2 phosphorylation in primary murine megakaryocytes
(MKs). Bone marrow (BM) (A) and fetal liver (FL)derived (B) mature MKs generated and isolated as described in Materials and Methods were har-
vested 4 hours at 37C in serum-free media and stimulated with 50 ng/mL murine TPO for the indicated times. ERK1/2 phosphorylation was evaluated by
immunoblot. To assess the effect of MEK inhibition on ERK1/2 activation, mature MKs were incubated with two specific MEK inhibitors, UO126
(10 mM) or PD184161 (10 mM) for 15 minutes followed by TPO stimulation for 10 minutes. Representative immunoblots of four independent experi-
ments are shown.
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adhere to the fibrinogen-coated coverslip for 5 hours at 37C.
Adhered MKs were fixed and labeled with a fluorescein isothiocya-
nate (FITC)anti-GPIIb antibody. Images were obtained using
a Zeiss 40 oil immersion 1.40 NA plan-apochromat lens on a Zeiss
Axiovert 200 M inverted high-end microscope and an Hamamatsu
Orca 285 cooled CCD camera. The percentage of proplatelet-form-
ing MKs and the area of proplatelet were analyzed. Slidebook and
Image J softwares were used to acquire and process images.
Quantitative real-time polymerase chain
reaction (PCR) determination of transcript levels
Total RNA was isolated using the RNeasy Kit (Qiagen, Crawley,
UK) according to the manufacturer’s instructions and contami-
nating genomic DNA removed by treatment with RNAse-free
DNAse kit (Qiagen). Single-stranded complementary DNA
(cDNA) was prepared using SuperScript III reverse transcriptase
with first-strand synthesis primed using oligo (dT). Quantitative
real-time PCR was performed using SYBR Green PCR master
mix. The reactions were carried in a Stratagene MX3000P system
(Stratagene, Leicester, UK). Levels of CXCR4 amplified cDNA
were normalized to the level of glyceraldehyde 3 phosphate dehy-
drogenase housekeeping control cDNA.
Statistical analysis
Experiments were performed a minimum of three times and repre-
sentative images are shown. Data is presented as mean 6 standard
error of mean and statistical analysis was conducted using two-tailed Student’s t-test. A p value !0.05 was considered statisti-
cally significant.Results
ERK1/2 is activated in response to
TPO in primary BM- and FL-derived MKs
Suspensions of mature BM- and FL-derived MKs were
generated by culturing freshly isolated hematopoietic
progenitor cells with TPO for 4 or 5 days, respectively,
and subsequent purification using a BSA gradient. Different
time points were used for the two populations, as the BM-
derived MKs were found to consistently reach a higher
level of maturity more rapidly that the FL-derived MKs.
The ability of TPO to activate the MEK-ERK1/2 pathway
in mature MKs was investigated by Western blotting.
BM- and FL-derived MKs display a rapid and transient
ERK1/2 phosphorylation upon stimulation by TPO, which
peaks at 5 to 10 minutes, before returning to almost basal
levels by 120 minutes (Figs. 1A and B; left-hand panels).
The decline in ERK1/2 phosphorylation was noticeably
more rapid in the BM-derived MKs. In both populations,
phosphorylation of ERK2 (corresponding to the lower
band) was more marked than ERK1. A similar set of
Table 1. Effect of MEK inhibitors on cell surface expression markers
% of positive cells
CD34 GPIIb GPIb
BM cells
Control 24.36 5.2 76.96 6.3 13.46 0.6
UO126 54.66 3.2 ** 76.26 2.1 0.46 0.3 **
PD184161 57.06 6.0 ** 81.46 3.7 1.6 60.7 **
FL cells
Control 15.46 2.8 55.86 2.7 7.56 5.2
UO126 30.66 0.9 ** 52.06 4.9 1.66 1.3 **
PD184161 36.46 4.8 ** 66.36 10.0 0.96 0.8 **
Percentage of positive cells was determined by flow cytometry using
specific CD34, GPIIb, and GPIb antibodies on the whole population prior
to bovine serum albumin (BSA) gradient. Mean 6 standard error of mean
of four independent experiments are shown. BM5 bone marrow; FL5 fe-
tal liver.
**p! 0.01, when compared with control.
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derived MKs by Rojnuckarin et al. [24]. These studies
were also performed on immature MKs at day 2 of differ-
entiation, by which time the maximal ploidy was 16N for
the BM-derived cells and 8 N for the FL-derived cells. A
similar profile of ERK1/2 activation to that in the mature
cells was observed but with a more rapid decline to the
baseline by 30 minutes in both cases (data not shown).
Basal and TPO-induced phosphorylation of ERK1/2 was
inhibited completely in the presence of the structurally
distinct MEK inhibitors, U0126 and PD184161 (Figs. 1A
and B; right-hand panels).ERK1/2-mediates differentiation
of primary BM- and FL-derived MKs
independent of p90 ribosomal S6 kinase (RSK)
The effect of inhibition of the MEK-ERK1/2 pathway on
BM- and FL-derived MK differentiation was investigated
using the specific MEK inhibitors, U0126 and PD184161.
Progenitors cells isolated from BM and FL were treated
with the two inhibitors along with TPO at the beginning of
the differentiation process. The inhibitor was also given
24 hours later as outlined in Supplementary Figure E1
(online only, available at www.exphem.org). Following
differentiation of BM- and FL-derived cells for 4 or 5 days,
respectively, the expression of the surface glycoproteins
CD34, GPIIb, and GPIb, and the degree of polyploidy were
examined. Flow cytometry profiles of the whole-cell popula-
tion prior to separation on the BSA gradient revealed that
the percentage of cells expressing GPIIb in the two models
was unchanged after treatment with UO126 or PD184161
(Table 1 and Fig. 2), suggesting that ERK1/2 is not involved
in the early stage of MK differentiation in either model.
Conversely, inhibition of MEK-ERK1/2 induced, in both
models, a significant increase in the percentage of cells
expressing CD34 and a corresponding reduction in thoseexpressing the late MK marker, GPIb (Table 1 and Fig. 2).
Inhibition of the MEK-ERK1/2 pathway also reduced the
overall DNA content (polyploidization) in the BSA gra-
dientenriched population of MKs, as analyzed by flow
cytometry after anti-GPIIb labeling and propidium iodide
staining (Figs. 3A and B). In the case of BM-derived MKs,
this was associated with an increase in polyploidy levels
between 8N and 16N and a reduction in cells with ploidy
values of 64N or 128N (Fig. 3A). Although FL-derived
MKs only generated ploidy levels up to 64N (Fig. 3B)
compare to 128N for BM-derived MKs (Fig. 3A), inhibition
of the MEK-ERK1/2 pathway caused a marked reduction in
the percentage of cells with polyploidy levels between
8N and 64N (Fig. 3B). The modal ploidy of BM- and FL-
derived MKs was also reduced following inhibition of the
MEK-ERK1/2 pathway (Figs. 3A and B). These data are in
agreement with the morphological analysis using May-Grun-
wald-Giemsa staining, which demonstrated a decrease in the
MK size and in the number of nuclear lobes in treated cells
compared to control cells (data not shown). Taken together,
these results demonstrate that the MEK-ERK1/2 pathway
plays a major role in the late stage differentiation of both
BM- and FL-derived MKs and is critical for full
polyploidization.
Many direct substrates of ERK1/2 are transcription
factors and kinases, including the p90 ribosomal S6 kinases,
RSK14. We therefore investigated the effect of a naturally
occurring RSK inhibitor, SL0101 [34], on development of
BM- and FL-derived MKs. In neither cell population did
the inhibition of RSK using SL0101 (10 mM) induce a change
in expression of the surface glycoproteins CD34, GPIIb, and
GPIb, or in the degree of ploidy (Supplementary Fig. E2,
online only, available at www.exphem.org), demonstrating
that regulation of megakaryopoiesis by TPO is not mediated
through activation of RSK.
p38MAPK is not required for MK differentiation
A similar set of studies to those described herewere carried out
in BM- and FL-derived MKs to investigate a possible role for
the p38MAPK pathway in differentiation. p38MAPK is
constitutively phosphorylated in both BM- and FL-derived
MKs and undergoes a decrease in phosphorylation upon TPO
stimulation at 30 and 90 minutes, respectively (Supplemen-
tary Fig. E3A, online only, available at www.exphem.org).
In view of the constitutive activation of p38MAPK, we inves-
tigated the effect of the p38MAPK inhibitor, SB203580, on
MK differentiation. These experiments were performed along-
side controls in the presence of indomethacin in view of the
ability of SB203580 to block cyclooxygenase [35]. Treatment
with SB203580 (10 mM) using the same protocol as that for
inhibition of the MEK-ERK1/2 pathway had no effect on
expression of CD34, GPIb, and GPIIb markers, or on the
degree of ploidy in either BM or FL-derived MKs relative to
controls (data not shown and Supplementary Fig. E3B, online
only, available at www.exphem.org). These results
Figure 2. Effect of MEK inhibitors on cell surface expression markers. Progenitor cells isolated from bone marrow (BM) (A) and from fetal liver (FL)
(B) were treated with the two MEK inhibitors U0126 (10 mM) or PD184161 (10 mM) along with thrombopoietin (TPO) (100 ng/mL) corresponding to
the beginning of the differentiation process and the inhibitor dose repeated 24 hours later. Four or five days after addition of TPO, expression of CD34,
GPIIb, and GPIb were evaluated by flow cytometry in the whole-cell population prior to bovine serum albumin (BSA) gradient (note that mature MKs
express a high level of GPIIb and GPIb are designated as R3; R4 correspond to the isotype-matched controls). Representative profiles from four independent
experiments are shown.
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Figure 3. Effect of MEK inhibitors on bone marrow (BM) and fetal liver (FL)derived megakaryocyte (MK) differentiation. Progenitor cells isolated from
BM (A) and FL (B) were treated with the two MEK inhibitors U0126 (10 mM) or PD184161 (10 mM) along with thrombopoietin (TPO) (100 ng/mL) cor-
responding to the beginning of the differentiation process and the inhibitor concentration was repeated 24 hours later. Four or five days after addition of TPO,
propidium iodide fluorescence histogram on GPIIb expressing cells showing polyploidy distribution of MKs was evaluated by flow cytometry. Representative
profiles from five independent experiments are shown. The percentage of cells with different polyploidy and the modal ploidy are mean 6 standard error of
mean of five independent experiments *p! 0.05; **p! 0.01, compared to control.
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MK differentiation.
ERK1/2 is involved in MK
migration in response to SDF1a gradient
It is recognized that as MKs mature and differentiate in the
BM, they migrate to sinusoidal BM endothelial cells, where
they form transendothelial projections called proplatelets[1,2]. In turn, these give rise to platelets, either before or after
release of proplatelets into the circulation. SDF1a is the
major chemotactic agent involved in regulation of MK
migration to the BM niche [36]. This stage of megakaryopoi-
esis can be followed in vitro by monitoring migration of MK
on fibronectin, a major extracellular matrix component in
BM [37], toward a gradient of SDF1a using a Dunn chamber.
We have used this approach to compare the ability of mature
Figure 4. Megakaryocyte (MK) migration toward a stromal-derived factor 1a (SDF1a) gradient. Bone marrow (BM) and fetal liver (FL)derived mature
MKs adherent on fibronectin (20 mg/mL)-coated coverslip were allowed to migrate toward an SDF1a gradient over 4 hours within the Dunn chamber as
described in Materials and Methods. PD184161 (10 mM) was added to the Dunn chamber outer well containing SDF1a (300 ng/mL). Representative differ-
ential interference contrast images from four independent experiments of primary MKs exposed to SDF1a gradient are shown (scale bar: 10 mm). The net
translocation distance (displacement from the start to the endpoint) of each cell is represented.
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respectively, to migrate along a SDF1a gradient.
In agreement with our previous results [32], BM-derived
MKs migrate toward a gradient of SDF1a, whereas, incontrast, FL-derived MKs do not migrate under the same
conditions (Fig. 4 and Supplementary Fig. E4, videos 1 and
2, online only, available at www.exphem.org). To investigate
a possible explanation for this difference, we measured the
Figure 5. CXCR4 expression in fetal liver (FL) and bone marrow (BM)derived megakaryocytes (MKs). (A) Relative CXCR4 mRNA expression of BM-
and FL-derived MKs normalized to the glyceraldehyde 3 phosphate dehydrogenase housekeeping complementary DNA was evaluated by real-time quanti-
tative polymerase chain reaction. Data are presented as mean 6 standard error of mean of three independent experiments. (B) CXCR4 surface expression of
BM- and FL-derived mature MKs was analyzed by flow cytometry using a fluorescein isothiocyanate (FITC)conjugated anti-CXCR4 antibody. Gray line
indicates relevant antibody control; black line, FITC-conjugated anti-CXCR4 antibody. Representative profiles from nine independent experiments are
shown. The percentage of cells expressing CXCR4 were quantified and presented as mean 6 standard error of mean.
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receptor, CXCR4, in both MK populations. CXCR4 tran-
script level analyzed by real-time quantitative PCR were
comparable in both models (Fig. 5A), whereas flow cytome-
try showed a robust surface expression of CXCR4 in BM-
derived MKs, but a negligible level on the FL-derived mature
MK surface (Fig. 5B), thereby accounting for the inability of
these cells to migrate to SDF1a. A negligible level of CXCR4
was also found on immature BM- and FL-derived cells (data
not shown). BM-derived progenitor cells, therefore, express
an increase in CXCR4 surface as megakaryocytic differenti-
ation proceeds, which are not observed in the FL cell model.
Consequently, we restricted our investigation of the role of
ERK1/2 and p38MAPK in migration to the population of
BM-derived MKs. Administration of the MEK inhibitor
PD184161 (10 mM) to the Dunn chamber caused the cells
to move relatively short distances and to more readily
change direction compared to control cells (Fig. 4 and
Supplementary Fig. E4, video 3, online only, available at
www.exphem.org), suggesting a lack of directed chemotaxis
in response to SDF1a. In contrast, inhibition of
p38MAPK using SB203580 had no effect on MK migration(Supplementary Fig. E3C and Fig. E4, videos 4 and 5, online
only, available at www.exphem.org). These results demon-
strate a critical role for ERK1/2 activation in migration of
BM-derived MKs.
ERK1/2 is required for proplatelet formation
MKs were grown to maturity from BM- and FL-derived
progenitors for 4 days and 5 days respectively, purified by
BSA gradient and then allowed to generate proplatelets
on an immobilized fibrinogen surface over a period of
5 hours. Although both populations of MKs were able to
generate proplatelets, approximately three times the
number of proplatelet-forming MKs were observed in the
FL-derived population, correlated to an increase of the total
surface area of the proplatelet network (Fig. 6A). As
a consequence, we restricted our investigation of the role
of the MEK-ERK1/2 pathway in proplatelet formation to
the FL-derived MKs. Inhibition of this pathway using two
specific inhibitors, U0126 and PD184161, reduced the
number of proplatelet-forming MKs byO50%, with a cor-
responding reduction in proplatelet area (Fig. 6B). In
contrast, inhibition of p38MAPK using SB203580 had no
Figure 6. Effect of extracellular signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) inhibition on proplatelet formation.
(A) Bone marrow (BM) and fetal liver (FL)derived mature megakaryocytes (MKs) were allowed to adhere on fibrinogen (100 mg/mL) coated coverslips
for 5 hours at 37C, fixed and labeled with a fluorescein isothiocyanate (FITC)anti-GPIIb antibody. Percent of proplatelet-forming MKs was analyzed and
proplatelet areas were quantified using Image J software. Data are presented as mean 6 standard error of mean (SEM) of three independent experiments.
(B) FL-derived mature MKs preincubated with U0126 (30 mM), PD184161 (10 mM), or SB203580 (10 mM) were allowed to adhere on fibrinogen, fixed and
labeled with a FITCanti-GPIIb antibody. Percent of proplatelet-forming MKs and proplatelet areas were quantified and data are presented as mean6 SEM
of three independent experiments. Representative GPIIb immunofluorescent images of proplatelet-forming MKs are shown (scale bar: 10 mm). (C) ERK1/2
phosphorylation was evaluated by immunoblot from whole cell lysates prepared from bovine serum albumin (BSA) nonadherent and fibrinogen adherent
MKs for the indicated times. Representative immunoblots of three independent experiments are shown.
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comparison to the indomethacin-treated control (Fig. 6B).
Together, these results suggest that ERK1/2 activation is
required in the process of proplatelet formation, whereas
p38MAPK is not involved. Interestingly, we observed
ERK1/2 phosphorylation in both MK populations at
1 hour after their adhesion to immobilized fibrinogen,
which returns to basal level by 5 hours (Fig. 6C).Discussion
In the present study, we have compared the ability of BM-
and FL-derived MKs to differentiate, migrate toward
a gradient of SDF1a, and generate proplatelets. The role
of MEK-ERK1/2 and p38MAPK pathways in these
processes has been investigated. The results demonstrate
a critical role for the ERK1/2 pathway, but not
p38MAPK, in all of these processes, as well as several
differences in the behavior of the two cell populations, of
which the most notable was the failure of the FL-derived
cells to migrate toward a gradient SDF1a due to a negligible
level of CXCR4 receptor surface expression.
MK differentiation is characterized by expression of
specific megakaryocytic surface glycoproteins and nuclear
maturation, resulting in large polyploidy cells. In this study,
the role of MEK-ERK1/2 pathway in the differentiation of
BM- and FL-derived MK was investigated using relatively
low concentrations of these two structurally distinct MEK
inhibitors, UO126 and PD186141. Inhibition of MEK-
ERK1/2 pathway is sufficient to induce an increase of expres-
sion of the immature marker CD34 and a decrease in the late
MK commitment marker, GPIb, without affecting expression
of the early megakaryocytic marker GPIIb. Furthermore,
inhibition of the MEK-ERK1/2 pathway causes a leftward
shift of the ploidy of the cells, showing a critical requirement
of MEK-ERK1/2 pathway in late stage of MK differentiation.
In contrast, the p38MAPK does not contribute to MK differen-
tiation. Indeed, Miyazaki et al. has shown that, in cord blood
primary MK, p38MAPK is required for TPO-induced
erythroid differentiation and not for MK differentiation [23].
During megakaryopoiesis, differentiating MKs migrate
within the complex BM stromal environment from the
endosteal niche to the BM sinusoidal endothelial cells,
the site of platelet formation. The chemokine SDF1a
augments this motility and promotes the interaction of
MKs with the BM vascular niche and, therefore, supports
thrombopoiesis [36]. Interestingly, we show that, contrary
to BM-derived MKs, MKs derived from FL are not able
to migrate in response to SDF1a because of a negligible
level of CXCR4 cell surface expression, despite compa-
rable level expression of CXCR4 gene in both models.
This suggests a different regulation of megakaryopoiesis
in these two models. One potential physiological explana-
tion for this is that MKs in the liver do not need to migrate
to release platelets because of a highly vascular environ-ment. In contrast, within the complex BM microenviron-
ment, MKs needs to migrate from the proliferative
osteoblastic niche to the capillary-rich vascular niche to
release platelets. Previous studies have revealed that
MAPKs are important factors in the regulation of cell
migration in numerous cell types in response to cell matrix
proteins, growth factors, or cytokines [38]. In this study, we
demonstrate a critical role for ERK1/2, but not p38MAPK,
in MK movement and chemotaxis in response to SDF1a.
The defective migration might be explained by the altered
polarization of the SDF1a receptor CXCR4, as shown
previously [32]. Moreover, ERK1/2 may govern cell move-
ment by phosphorylating the myosin light-chain kinase, the
protease calpain, or the focal adhesion kinase. These phos-
phorylations regulate the dynamics of focal adhesions and
the reorganization of cytoskeleton, which are critical for
cell migration [3941]. Further studies will focus upon
elucidating the precise mechanisms by which ERK1/2
control cell migration.
The role of MEK-ERK1/2 and p38MAPK pathways in
the terminal stage of megakaryopoiesis, proplatelet forma-
tion, was also investigated. An increased proportion of FL-
derived MKs generate proplatelets compared to BM-
derived MKs, perhaps reflecting the need to generate a large
number of platelets in parallel to development of the vascu-
lature in the fetus, whereas in contrast, the role of BM-
derived MKs is to maintain a steady-state platelet produc-
tion. Interestingly, in culture conditions, BM-derived MKs
present a higher ploidy, but form fewer proplatelets than
FL-derived MKs, suggesting that a higher threshold of
MK maturation may be necessary to achieve proplatelet
formation in BM. The present study also demonstrates
that MEK-ERK1/2 pathway, but not p38MAPK, is required
for proplatelet generation. It is now well-established that
dynamic regulation of microtubules is essential for propla-
telet formation [4244] and that microtubule-associated
protein, which are well-characterized substrates of MAPKs
[45,46], play a major role in microtubule dynamics [47].
One of the potential mechanisms implicating ERK1/2 in
proplatelet formation is therefore the regulation of the
phosphorylation states of the microtubule-associated
proteins and subsequent organization of the microtubule
network.
In summary, we provide evidence for the critical role of
the MEK-ERK1/2 pathway, but not p38MAPK, in MK
differentiation, migration, and proplatelet formation, and
describe several differences in the behavior of the two
primary MK populations from BM and FL. Further exper-
iments are required to identify and confirm the roles of
the substrates of ERK1/2 that underlie these effects.Acknowledgments
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Supplementary methods
Reagents, antibodies, and suppliers
Recombinant murine TPO, murine SCF, and murine SDF1a were
purchased from PeproTech (London, UK). Sheep anti-rat IgG Dynabeads,
biotin-conjugated rat anti-mouse CD45R/B220, purified rat anti-mouse
CD16/CD32, FITC- or PE-conjugated anti-mouse GPIIb were from BD
Pharmingen (Oxford, UK). PE-conjugated anti-mouse GPIb antibodies
were from EMFRET Analytics (Eibelstadt, Germany). Anti-mouse Ly-
6G, biotin anti-mouse CD11b and FITC-conjugated anti-mouse CD34 anti-
bodies were from eBioscience (Wembley, UK). Anti-mouse CD49e anti-
body was from Serotec (Oxford, UK). Stempro medium and Dulbecco’s
modified Eagle’s medium were from GIBCO, Invitrogen (Paisley, UK).
The p38MAPK inhibitor, SB203580, was obtained from Calbiochem (Not-
tingham, UK). The MEK inhibitor PD184161 was a gift from Pfizer Global
Research and Development (Sandwich, UK). The MEK inhibitor U0126
and the polyclonal antibody directed against the phosphorylated form of
p38MAPK were purchased from Promega Corp. (Madison, WI, USA).
The monoclonal anti-phospho-ERK1/2, the polyclonal anti-p38MAPK,
the goat anti-rabbit-horseradish peroxidase and goat anti-mouse-horse-
radish peroxidase antibodies were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). SL0101, a specific RSK inhibitor, was
purchased from Toronto Research Chemicals (North York, Canada).
FITC conjugated anti-mouse CXCR4 antibody was from R&D Systems
(Abingdon, UK). All other reagents were purchased from Sigma-Aldrich
(St Louis, MO, USA).
Flow cytometry
Expression levels of GPIIb, GPIb, and CD34 were measured by flow
cytometry. Aliquots of TPO-culture whole cell population before BSA
gradient were stained with 2.5 mL FITC-anti-GPIIb, PE-anti-GPIIb,
FITC-anti-GPIb, or FITC-anti CD34 antibodies in 50 mL 1% BSA/PBS
for 30 minutes at room temperature. Relevant isotype-matched controls
directly conjugated to FITC or PE were used as controls. Samples were
acquired using FACSCalibur flow cytometer and CellQuest software (Bec-
ton Dickinson, Oxford, UK) and analyzed using Summit v4.3 software
(DAKO, Cambridge, UK).
MK ploidy
Following labelling with FITC-anti-GPIIb, mature MKs were fixed
with 1% paraformaldehyde for 45 minutes at 4C, and then washed with
PBS. MK polyploidy was analyzed following DNA staining with 0.01
mg/mL propidium iodide in solution containing 2 mM MgCl2, 0.05%
saponin, and 10 U/mL RNAse A. Samples were acquired using FACSCa-
libur flow cytometer and CellQuest software (Becton Dickinson, Oxford,
UK) and analyzed using Summit v4.3 software (DAKO, Cambridge,
UK). DNA plots were taken from GPIIb expressing cells only.
Cell migration assay
Chemotaxis was assessed using the Dunn chamber (Weber Scientific
International, Teddington, UK). BM-derived mature MK suspension was
applied on fibronectin-coated (20 mg/mL) coverslips in complete medium
and left at 37C for 1 hour for cells to adhere. The coverslip was then
placed directly onto the Dunn chamber where both the inner and the outer
wells were filled with medium. Using sterile filter paper, the outer well was
drained to leave the inner well and the region over the bridge filled with
medium. The outer well was then refilled with the same medium contain-
ing 300 ng/mL SDF1a. The Dunn chamber was placed in a humidified
chamber on a heated stage at 37C within an inverted microscope. Time-
lapse images were digitally captured every minute for 4 hours using a Zeiss
40  oil immersion 1.40 NA plan-apochromat lens on a Zeiss Axiovert
200 M inverted high-end microscope (Welwyn Garden City, UK) and an
Hamamatsu Orca 285 cooled CCD camera.Zeiss Axiovert 200 inverted
high-end microscope and Hamamatsu Orca 285 cooled digital camera.
To track migration paths, a series of images were analyzed using Slidebook
and Image J software, and the data were plotted with Microsoft Excel. Net
translocation distance was determined as the straight distance between the
endpoints during the 4 hour-period.
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Supplementary Figure E1. Bone marrow (BM)- and fetal liver (FL)-derived megakaryocyte (MK) purification and culture. (A) BM cells were obtained
from femora and tibiae of C57BL6 mice by flushing and CD16/CD32þGr1þB220þCD11bþ cells were depleted using immunomagnetic beads (sheep
anti-rat IgG Dynabeads). The remaining population was cultured in 2.6% serum-supplemented Stempro medium with 2 mM L-glutamine, penicillin/strep-
tomycin, and 20 ng/mL murine stem cell factor (SCF) at 37C under 5% CO2 for 2 days. Cells were then cultured for an additional 4 days in the presence
of 20 ng/mL murine SCF and 100 ng/mL murine thrombopoietin (TPO) [data from 30,32]. (B) FL cells were obtained from whole livers recovered from
mouse fetuses between embryonic days 13 and 15. Single-cell suspensions were prepared by successive passage through 19-, 22-, and 25-gauge needles
and cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, penicillin/streptomycin, and 100
ng/mL murine TPO for 5 days [data from 31]. After 4 to 5 days of culture in the presence of TPO, cell population was enriched on mature MKs after
1.5%/3% bovine serum albumin (BSA) gradient under gravity (1g) for 45 minutes at room temperature. The proportion of mature MKs in the enriched pop-
ulation was estimated to O60% (data not shown). To study the role of mitogen-activated protein kinase (MAPK) in differentiation, inhibitors (Inh) were
added at the same time than TPO corresponding to the beginning of the differentiation process (day 0) and the inhibitor dose were repeated after 24 hours
(day 1).
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Supplementary Figure E2. Effect of p90 ribosomal S6 kinase (RSK) inhibitor on fetal liver (FL)derived megakaryocyte (MK) differentiation. Cells
derived from FL were cultured with murine thrombopoietin (TPO) 100 ng/mL supplemented or not with SL0101 (10 mM) as described in Figures 1 and
3. (A) Expression of CD34, GPIIb, and GPIb were evaluated by flow cytometry of the whole-cell population prior to bovine serum albumin (BSA) gradient.
The percentage of positive cells for the different markers is mean6 standard error of mean of three independent experiments. (B) FL-derived MKs after BSA
gradient were stained with propidium iodide. Ploidy was evaluated by flow cytometry of MK culture grown in the presence of 100 ng/mL TPO in combination
with methanol (control) or SL0101 (10 mM). GPIIb-positive cells were gated to analyze for DNA content. The percentage of cells with different polyploidy
are mean from three independent experiments 6 standard error of mean.
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Supplementary Figure E3. Time course of thrombopoietin (TPO)-induced p38 mitogen-activated protein kinase (MAPK) phosphorylation and effect of
p38MAPK inhibitor on megakaryocyte (MK) endomitosis and migration. (A) Bone marrow (BM)- and fetal liver (FL)-derived mature MKs were harvested
4 hours at 37C in serum-free media before stimulation with 50 ng/mL murine TPO for the indicated times. p38MAPK phosphorylation was evaluated by
immunoblot. (B) Mature BM- and FL-derived MKs were cultured with murine 100 ng/mL TPO in the presence of indomethacin (5 mM) (control) or in combi-
nation with SB203580 (10 mM) as described in Figures 1 and 3. Ploidy was evaluated by flow cytometry (propidium iodide staining) of mature MKs. The
percentage of cells with different polyploidy and the modal ploidy are mean 6 standard error of mean of five independent experiments.
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Supplementary Figure E3. (Continued). Representative polyploidy profiles are shown (C) BM-derived mature MKs were allowed to migrate headed for the
Dunn chamber outer well containing stromal-cell-derived factor 1 a (SDF1a) and SB203580 (10 mM) for 4 hours. The net translocation distance (displace-
ment from the start to the endpoint) of each cell is represented and is a total of four independent experiments.
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